Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

Launched by ALEXANDRIA UNIVERSITY · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different medications, Rivaroxaban and Enoxaparin, to see which one is more effective at preventing blood clots in patients who are morbidly obese and are preparing for bariatric surgery, which is a type of weight loss surgery. Blood clots can be a serious risk for patients undergoing surgery, so finding the best way to prevent them is important.

To be eligible for this study, participants should be between 20 and 60 years old, have a body mass index (BMI) between 35 and 50, and be in relatively good health (not having severe heart, kidney, or liver problems, or major psychological disorders). The trial is currently recruiting participants, so if you meet these criteria, you may have the opportunity to take part. If you join, you will be randomly assigned to receive either Rivaroxaban or Enoxaparin, and the study will monitor your health to see how well these medications work in preventing blood clots.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 20-60 years, both sexes.
• • ASA physical status class I to III.
• • BMI 35-50 kg/m²
• Exclusion Criteria:
• • Severe cardiac disorder
• • chronic renal failure
• • liver cirrhosis
• • major psychological disorder